Navigation Links
Adaptive Announces a Biomarker Discovery Agreement with Johnson & Johnson Innovation
Date:1/13/2014

SEATTLE, Jan. 13, 2014 /PRNewswire/ -- Adaptive Biotechnologies announced today a biomarker discovery agreement facilitated by the Johnson & Johnson Innovation Center in California.  Under the agreement, Adaptive will use its patented immune profiling assay, immunoSEQTM, to enable an in-depth characterization of the immune response to diseases being studied and select immunology and oncology drugs being developed by Janssen Research & Development, LLC (Janssen). The exploration of immune response may identify patient populations more likely to respond to targeted therapies based on their immune status.

(Logo: http://photos.prnewswire.com/prnh/20120103/SF28632LOGO)

"We are delighted to work so closely with Janssen to further elucidate the role that immune profiling can play in scientific research and drug development," said Chad Robins, CEO and Founder of Adaptive Biotechnologies. "Adaptive's corporate focus is to further understand the immune response in patients living with diseases like cancer and autoimmune disorders."

Adaptive's CEO Robins will be sharing this corporate focus on immune profiling to improve patient care during the upcoming JP Morgan Healthcare conference in San Francisco on January 15, 2014. Details on Adaptive's full suite of research and diagnostic immunosequencing assays, as well as other key partnerships, will be presented.

About Adaptive 
Adaptive Biotechnologies Corporation ("Adaptive" or the "Company") is a pioneer in immunosequencing diagnostics, with a focus in oncology. The Company leverages advances in next generation sequencing ("NGS") to profile T-Cell and B-Cell Receptors ("TCRs" and "BCRs").  This patented breakthrough enables in-depth characterization of the immune system, which is the primary defense against cancer. By incorporating immunosequencing into clinical care, Adaptive can enhance the diagnosis, prognosis, and monitoring of cancer patients. The Company's first clinical application, clonoSEQTM, is for monitoring Minimal Residual Disease ("MRD") in blood-based cancers.  The Company recently launched clonoSEQTM as a CLIA certified Laboratory Developed Test ("LDT") in the second quarter of 2013. Improving the ability to accurately detect and track residual disease at a molecular level affords clinicians the potential to detect relapse earlier and improve patient care.  Adaptive is currently validating additional oncology diagnostics to quantify the presence and clonality of Tumor Infiltrating Lymphocytes ("TIL") and to create a reliable measure of "immunocompetency" to predict or monitor response to cancer treatments that directly alter the host immune system. Adaptive incubates and validates potential clinical products by offering fee-for-service access to its proprietary immune profiling sequencing technology under the brand name immunoSEQTM.


'/>"/>
SOURCE Adaptive Biotechnologies Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sleep Apnea Diagnostic & Therapeutic Devices Market [Polysomnographs, Respiratory Polygraphs, Pulse Oximeters, CPAP, Masks, Adaptive Servo-Ventilation (ASV), Oral Appliances, Nasal EPAP, Neurostimulation] Global End-user Analysis, Competitive Landsc
2. Accelerating Drugs to Market - Despite Challenges, Adaptive Clinical Trials Reduce Drug Development Costs and Time to Market
3. SynteractHCR Enhances Adaptive Trial Capabilities
4. Health Decisions CEO Michael Rosenberg, MD, MPH, Offers Insights into Adaptive and Risk-Based Monitoring in the Journal of Clinical Research Best Practices
5. Elsevier Launches Adaptive Quizzing Solution For Nursing Students
6. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
7. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
8. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
9. Misonix Announces New Distribution Agreement For Panama
10. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)...  Getinge, a leading global provider of innovative ... program -- "Color for the Kids!" -- to ... by The Children,s Heart Foundation. Pediatric patients and ... encouraged to download a coloring picture at ... the gallery on the website. For each artwork ...
(Date:9/1/2017)... PALMER, Mass. , Sept. 1, 2017 ... Complete HealthCare Solutions, Inc , highlights opportunities for growth ... Street Journal report that Marlin Equity is seeking a ... is an annual award-winning 22-year-old healthcare solutions Value Added ... market.  "As the ...
(Date:8/31/2017)... , Aug. 31, 2017 PM360,s annual ... guide to the latest innovations happening across the industry. ... publication to focus on providing a comprehensive look at ... issue covers the most innovative companies, startups, divisions, products, ... "Everyone in this industry wants ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... 2017 , ... The Semper Fi Fund, one of the nation’s highest-rated veteran ... of videos and a compelling documentary that provide unique insights and powerful advice to ... of its ongoing mission. , Each of the videos focuses on a specific issue ...
(Date:9/19/2017)... Delaware (PRWEB) , ... September 19, 2017 , ... Driving ... and Safety Training Company by Training Industry Inc. as part of its mission to ... , Selection to the first annual 2017 Top 20 Health and Safety Training ...
(Date:9/19/2017)... ... September 19, 2017 , ... The ISO 9001 standard sets out the ... become more efficient and improve customer satisfaction. ISO 9001:2015 was released in 2015 and ... a deadline of September 2018. , As described in this white ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... Colleyville, TX, announces the launch of its magnesium-based orthopedic medical device, OsteoCrete®. OsteoCrete® ... it’s the first in the U.S. to incorporate magnesium, a critical property for ...
(Date:9/19/2017)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... Director of its Pflugerville- FM 685 facility. , “We are pleased to announce ... location,” said Dr. Stephen Van Roekel, Reginal Medical Officer of First Choice Emergency Room ...
Breaking Medicine News(10 mins):